Ryan Quigley has been appointed as the new Chief Executive Officer at Inizio. He succeeds Paul Taaffe, who will continue to work with Ryan to support the transition until the end of the year.
Since 2021, Ryan has been Chief Operating Officer at Inizio, driving the company’s commercial strategy, innovation agenda and investment roadmap, as well as playing a pivotal role in developing Inizio as a commercialisation partner to global health and life sciences companies.
Prior to his current role, Ryan’s 25-year career included roles at some of the world’s largest healthcare and pharmaceutical companies. Most notably, he held senior leadership roles at Abbott and AbbVie, where he was responsible for launching blockbuster brands across major markets.
Ryan said: “This is an exciting time to lead Inizio as we continue to grow and help biopharma clients with integrated solutions to bring highly complex new drugs to market. At Inizio, we connect talent from across the organisation to create innovative solutions that make a meaningful difference for our clients and patients. Together, we will continue to unlock new opportunities and reimagine how healthcare engages with patients, professionals and society.”
Liam FitzGerald, Chairman of the Board, said: “Ryan has an exceptional track record as a leader who combines strategic vision with deep operational expertise. He embodies the values of Inizio and has the energy, ambition and client focus to lead the business into its next chapter of growth and success.”